bioihbjkbjnl/mcl2 huggingface dataset:
The Effect of Neuromuscular Exercise Training on Balance, Jump and Trunk Endurance in Female Ice Hockey Players
Condition: Sports Physical Therapy
Study type: Interventional

Summary: 
      The aim of the study is to investigate the changes in dynamic balance, vertical jump and
      trunk endurance parameters in athletes included in body weight neuromuscular program in
      addition to regular training programs.
    

Detailed description: 
      As a randomization method, the participants will be divided into two groups as control and
      experimental groups by using a computer-based program and a simple randomization method. This
      study will be scheduled five times a week for six weeks. After the evaluations, all exercises
      will be taught to the experimental group by the physiotherapist. While the experimental group
      will apply to this program and traditional education, the control group will continue to the
      traditional education program. Since all exercises are done with body weight, no extra
      equipment will be needed. Reviews:

      Balance evaluation: Y balance test The Vertical Jump Test will be used to evaluate muscle
      strength in the lower extremities.

      McGill Trunk Endurance Test: To be used for Muscular Endurance Assessment.
    

Intervention name(s): exercise; control
Intervention type(s): Other; Other
Intervention description(s): Exercises:
Lunge to Hamstrings Stretch 3 sets of 30 seconds
Standing Hip Out 3 sets of 30sec
90-90 Hip Stretch 3 sets of 30 seconds
World's Greatest Stretch 3 sets of 30 seconds
Star Excursion 3 sets of 5 reps
Side Jumps+ Balance 3 sets of 10 reps
Forward Hops + Balance 3 sets of 10 reps
Squat 3 sets of 10 reps
Squat Jump 3 sets of 10 reps
Jumping Spider Push-up 3 sets of 10 reps
Double Leg Vertical Jump 3 sets of 10 reps
Broad Jumps 3 sets of 10 reps
Lateral Box Shuffles 3 sets of 10 reps
Plank 3 sets of 30 seconds
Side Plank 3 sets of 30 seconds
Bird Dog 3 sets of 10 reps
Glute Bridge 3 sets of 10 reps
Single Leg Glute Bridge 3 sets of 10 reps
Single Toe Raises 3 sets of 30sec
Nordic Hamstrings 3 sets of 10 reps
Monster Walk 3 sets of 10 reps; The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: The intervention group will be given neuromuscular exercises 5 days a week for 12 weeks.
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Ice hockey; Neuromuscular exercise; Vertical jump; Trunk endurance; Y balance
Cochlear Implantation in Pediatric Cases of Unilateral Hearing Loss
Condition: Hearing Loss, Unilateral
MeSH terms: Hearing Loss; Deafness; Hearing Loss, Unilateral
Study type: Interventional

Summary: 
      This feasibility study evaluates whether children with unilateral, moderate to profound
      sensorineural hearing loss experience an improvement in speech perception, hearing in noise,
      localization, and quality of life with a cochlear implant as compared to an unaided listening
      condition.
    

Detailed description: 
      Unilateral hearing loss (UHL) is a term used to describe a substantial hearing loss in one
      ear and normal hearing in the contralateral ear. Despite normal hearing in one ear, these
      individuals experience reduced speech perception in noise, variable abilities on localization
      tasks, increased reports of hearing handicap, reduced quality of life, and often, they obtain
      limited or no benefit from conventional amplification. In the United States, the prevalence
      of UHL in children ranges from 0.03% to 3%, depending on the age of the child.

      Cochlear implantation performed for children with bilateral, severe to profound deafness has
      significant impacts on several aspects of child development.

      The practice of providing cochlear implants to children who have significant hearing loss in
      one ear is of great interest and is occurring with greater frequency as reported in case
      studies and small set clinical reports. The primary purpose of this feasibility study is to
      demonstrate the effectiveness of cochlear implantation in children, age 3 years 6 months to 6
      years, 6 months, with moderate to profound UHL. Postoperative results will be evaluated with
      speech perception measures, localization tasks, hearing in noise tasks, and subjective
      reports.
    

Intervention name(s): Cochlear implant
Intervention type(s): Device
Intervention description(s): Implantation
Other intervention name(s): MED-EL Cochlear Implant; MED-EL Synchrony with FLEX 28 array; MED-EL Synchrony with FLEX 24 array
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: cochlear implant
Topic Insulin Accelerates Wound Healing in Diabetes
Condition: Diabetes Mellitus; Wounds
MeSH terms: Diabetes Mellitus; Wounds and Injuries
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      The purpose of this study is to determine whether topic insulin is effective to accelerates
      wound healing in diabetes patients
    

Detailed description: 
      Wound healing is impaired in diabetes mellitus, but the mechanisms involved are not well
      established. The purpose of this study was to investigate the effect of a topic insulin cream
      on wound healing in diabetic patients. age eligible for study:18 years old-older gender
      eligible for study:both accepts healthy volunteers:no have a proband with T1DM or T2DM. A
      proband is an individual with more than one year of diagnosis.

      have proband with a wound that is difficult to be healed for at least three months.

      patients with serum creatinine <1.5mg/dl Does not satisfy the above inclusion criteria
      infection diagnosed wound patients with cellulitis, venous stasis, inadequate perfusion,
      osteomyelitis and patient's inability to attend clinics for follow up
    

Intervention name(s): topic cream insulin
Intervention type(s): Drug
Intervention description(s): Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
Other intervention name(s): wound healing; insulin cream; diabetes
Intervention MeSH terms: Insulin; Insulin, Globin Zinc
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: wound healing; diabetes mellitus
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
MeSH terms: Urticaria; Chronic Urticaria
Study type: Interventional
Phase: Phase 2

Summary: 
      This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to
      severe chronic urticaria who exhibit IgE against thyroperoxidase.
    


Intervention name(s): Omalizumab 75-375 mg; Placebo to omalizumab; Loratadine; Clemastine
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.; Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.; All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.; All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
Other intervention name(s): Xolair; Lorano®; Tavegil®
Intervention MeSH terms: Omalizumab; Loratadine; Clemastine; Antibodies, Monoclonal
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Chronic urticaria, omalizumab, thyroperoxidase, IgE
Predictive Value of Dynamic Combination of BNP and NGAL for the Prognosis of Patients With Sepsis
Condition: 28-day Mortality; Sepsis
MeSH terms: Sepsis; Toxemia
Study type: Interventional

Summary: 
      Objective: to clarify the predictive value of brain natriuretic peptide (BNP) in combination
      with neutrophil gelatinase associated lipocalin (NGAL) for the prognosis of patients with
      sepsis.
    


Intervention name(s): BNP and NGAL
Intervention type(s): Other
Allocation: Non-Randomized
Intervention model: Factorial Assignment
Masking: None (Open Label)
Primary purpose: Screening
Keywords: BNP; NGAL; Sepsis; Mortality
The Effect of Positive End Expiratory Pressure (PEEP) During Laparoscopic Cholecystectomy
Condition: Brain Ischemia
MeSH terms: Brain Ischemia; Ischemia
Study type: Interventional

Summary: 
      During the laparoscopic cholecystectomy, Pneumoperitoneum could affect to the regional oxygen
      saturation of brain. positive end expiratory pressure (PEEP)could improve the respiratory
      parameters include oxygenation. So applying PEEP could improve the regional brain oxygen
      saturation (rSO2)
    

Detailed description: 
      During the laparoscopic cholecystectomy, Pneumoperitoneum could affect to the regional oxygen
      saturation of brain due to increased intracranial pressure, central venous pressure and make
      worse to respiratory parameters. Positive end expiratory pressure could improve the
      respiratory parameters include oxygenation. So applying PEEP could improve the regional
      oxygen saturation of brain during the pneumoperitoneum during the laparoscopic
      cholecystectomy.
    

Intervention name(s): PEEP; ZEEP
Intervention type(s): Other; Other
Intervention description(s): applying PEEP 0 cmH2O during pneumoperitoneum continuously; applying PEEP 10 cmH2O during pneumoperitoneum continuously
Other intervention name(s): PEEP 0; PEEP 10
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Prevention
Keywords: laparoscopic cholecystectomy; PEEP; rSO2
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
Condition: Urinary Bladder, Neurogenic
MeSH terms: Urinary Bladder, Neurogenic
Study type: Interventional
Phase: Phase 3

Summary: 
      The objective of the study is to find out if the medicine fesoterodine is a useful treatment
      in children with bladder muscle overactivity caused by a neurological condition. Children
      will be aged 6 to 17 years old. This is done by finding out how well it works, what the body
      does to fesoterodine, what side effects are experienced and the safety of fesoterodine. It
      will be compared with the medicine oxybutynin, which is already available for treating the
      condition.
    


Intervention name(s): Fesoterodine PR 4 mg; Fesoterodine PR 8 mg; Fesoterodine PR 8 mg; Oxybutynin; Fesoterodine PR; Fesoterodine BIC 2 mg; Fesoterodine BIC 4 mg
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): Fesoterodine 4 mg tablet once daily for 24 weeks; Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.; Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.; Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.; Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.; Fesoterodine BIC 2 mg tablet once daily for 24 weeks.; Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
Other intervention name(s): Safety extension phase
Intervention MeSH terms: Fesoterodine; Oxybutynin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: neurogenic detrusor overactivity; neurogenic bladder; neuropathic bladder; neurologic disease; fesoterodine
Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects
Condition: Healthy Subjects
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary purpose of this study is to evaluate the effect of repeated doses of selexipag on
      the pharmacokinetics of a single oral dose of midazolam (i.e., how long and how much
      midazolam is present in the blood)
    

Detailed description: 
      In order to exclude an inductive effect of selexipag in the gastrointestinal tract, this
      study aims at investigating the effect of selexipag on the PK of midazolam, a sensitive
      substrate of both hepatic and intestinal cytochrome P450 3A4 (CYP3A4).
    

Intervention name(s): Midazolam; Selexipag
Intervention type(s): Drug; Drug
Intervention description(s): Single oral dose of 7.5 mg midazolam (tablet); Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
Other intervention name(s): ACT-293987
Intervention MeSH terms: Selexipag; Midazolam
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Keywords: selexipag; pharmacokinetics; midazolam
Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
Condition: End-stage Renal Disease; Kidney Failure, Chronic
MeSH terms: Kidney Diseases; Kidney Failure, Chronic; Renal Insufficiency
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered
      vascular prosthesis, the Human Acellular Vascular Graft, HAVG.

      The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the
      creation of vascular access for dialysis.
    

Detailed description: 
      The HAVG is a sterile, non-pyrogenic, acellular tubular graft composed of human collagens and
      other natural extra-cellular matrix proteins. Upon implantation, it is anticipated (based on
      pre-clinical studies) that the collagen-based matrix comprising the graft will be infiltrated
      with host cells and re-modeled by the host. This will result in a vascular structure more
      similar to the histological composition of the native vascular tissue that may improve graft
      longevity and be less likely to become infected.
    

Intervention name(s): HAVG
Intervention type(s): Biological
Intervention description(s): HAVG is implanted into patients' arm.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: End-stage Renal Disease; Hemodialysis; Chronic Renal Insufficiency; Renal Dialysis; Hemodiafiltration; Blood Vessel Prosthesis; Tissue-Engineered Vascular Graft; Vascular Prosthesis Implantation; Kidney Diseases; Kidney Failure, Chronic; Renal Insufficiency; Urologic Diseases
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
Condition: Wrinkle; Fine Lines; Crepey Skin; Acne Scars; Acne; Enlarged Pores; Stretch Marks; Loose Skin
MeSH terms: Skin Diseases; Striae Distensae
Study type: Interventional

Summary: 
      Subjects are to be enrolled in this clinical study if they are 18 - 55 years old. Up to 120
      subjects will be enrolled at multiple study centers. Subjects may receive up to 5 treatments
      for a wide array of dermatologic conditions in which electrocoagulation and hemostasis is a
      viable mechanism for means of improvement.
    


Intervention name(s): Potenza
Intervention type(s): Device
Intervention description(s): Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)
Condition: Fibromyalgia
MeSH terms: Fibromyalgia; Myofascial Pain Syndromes
Study type: Interventional

Summary: 
      The main objective of this study is to analyse the effectiveness of the FIBROWALK
      multicomponent treatment program as coadjuvant of treatment-as-usual (TAU) compared to TAU
      alone.
    

Detailed description: 
      This is a two-arm RCT focused on the potential efficacy of the multicomponent program
      FIBROWALK as coadjuvant of treatment-as-usual (TAU) vs. TAU alone. FIBROWALK combines
      multicomponent approach based on Pain Neuroscience Education (PNE), therapeutic exercise,
      Cognitive Behavioural Therapy (CBT) and Mindfulness training.

      The main objective of this RCT was two-fold: (a) To analyse the effectiveness of a 12-week
      multicomponent treatment as an add-on to Treatment (FIBROWALK) as Usual (TAU) to improve
      functional impact (primary outcome), as well as pain, fatigue, kinesiophobia, physical
      function, anxiety, and depressive symptoms (secondary outcomes) compared to TAU; and (b) to
      explore the baseline differences between responders and non-responders in terms
      sociodemographic and clinical characteristics.
    

Intervention name(s): TAU + multicomponent treatment FIBROWALK; Treatment as Usual (TAU)
Intervention type(s): Behavioral; Behavioral
Intervention description(s): Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):
Pain neuroscience education (30 min.)
Cognitive restructuring (30min.)
Mindfulness techniques (30 min.)
Physical exercise(30 min.)
Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.; Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Parallel Assignment Single-blind, parallel-group, randomized controlled trial
Masking: Double (Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: multicomponent treatment; chronic pain; Fibromyalgia; pain neuroscience education; therapeutic exercise; cognitive behavioural therapy; mindfulness; randomized controlled trial
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Condition: Glioblastoma; Gliomas
MeSH terms: Glioblastoma; Glioma
Study type: Interventional
Phase: Phase 2

Summary: 
      Patients have a newly diagnosed brain tumor called a malignant glioma and participate in the
      study to see if it is possible to increase the benefit of temozolomide when given after
      radiation. A recent study showed that patients with newly diagnosed glioblastoma lived longer
      when treated with both temozolomide and radiotherapy followed by 6 months of temozolomide
      than patients treated with radiotherapy alone. Patients will receive standard low dose
      temozolomide during radiation. After radiation, they will be randomized to receive either
      more intense temozolomide or continuous low dose temozolomide.
    

Detailed description: 
      This is a randomized phase II study that will test two different adjuvant temozolomide
      regimens in patients with newly diagnosed glioblastoma multiforme. The goal of this study is
      to identify a regimen that would be appropriate to bring to a phase III trial and compare to
      the standard dosing regimen of temozolomide recently reported by Stupp et al. in the New
      England Journal of Medicine. Secondary goals of this study include: prospective analysis of
      the prognostic impact of MGMT status and generation of preliminary data regarding this
      treatment strategy for other types of malignant glioma.

      The decision regarding which treatment patients receive is made randomly. Neither them or
      their doctor can select which treatment the patient will receive. There is reason to believe
      that both of these doses may benefit treating your brain tumor. After 6 months of
      chemotherapy, and assuming the brain tumor has not shown any sign of growth, they will begin
      receiving cis-retinoic acid. Cis retinoic acid has been shown in one study to possibly
      prevent or delay tumor recurrence.
    

Intervention name(s): Temozolomide; Temozolomide
Intervention type(s): Drug; Drug
Intervention description(s): Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.; Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
Intervention MeSH terms: Temozolomide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment